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Abstract
Purpose: To develop an oral formulation of amphotericin B (AmB) that is stable at the temperatures of WHO Climatic Zones
3 and 4 (30–43uC) and to evaluate its efficacy in a murine model of visceral leishmaniasis (VL).
Methods: The stability testing of four novel oral lipid AmB formulations composed of mono- and di-glycerides and
pegylated esters (iCo-010 to iCo-013) was performed over 60 d and analyzed by HPLC-UV. In addition, the four formulations
were incubated 4 h in fasted-state simulated intestinal fluid. AmB concentration was measured spectrophotometrically and
emulsion droplet diameter was assessed by dynamic light scattering. Antileishmanial activity of iCo-010 was evaluated at
increasing oral doses (2.5 to 10 mg/kg) in a murine model of VL.
Results: AmB stability in the lipid formulation (iCo-010) was .75% over 60 days. After 4 h in fasted-state simulated
intestinal fluid, AmB concentration was .95%. iCo-010 demonstrated significant efficacy when orally administered to VL-
infected mice bid for five days (inhibition of 99%, 98%, and 83% at 10, 5 and 2.5 mg/kg compared to the vehicle control). In
addition, the qd dose of 20 mg/kg provided 96% inhibition compared to the vehicle control.
Conclusions: The oral AmB formulation iCo-010 is stable at the temperatures of WHO Climatic Zones 3 and 4 (30–43uC). iCo-
010 showed excellent antileishmanial activity at both 10 mg/kg po bid for 5 days (,99% reduction in parasitic infection) and
20 mg/kg po qd for 5 days (95% inhibition when compared to control).
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Introduction
Visceral leishmaniasis (VL) is a systemic form of a vector-borne
parasitic disease caused by obligate intra-macrophage protozoa of
the genus Leishmania. VL is transmitted via the bite of an infected
sand fly [1,2]. The parasites are then disseminated through the
vascular and lymphatic systems, infecting monocytes and macro-
phages of the reticulo-endothelial system and accumulating in the
liver and spleen [1].
VL is always fatal in humans if left untreated [3]. Unfortunately,
the treatment options for VL are limited. Amphotericin B (AmB),
a polyene antibiotic, is the most active antileishmanial agent that
currently exists. Liposomal AmB (AmBisome) is used as first-line
treatment in developed countries [1,7,8,9,10]; however, the
requisite parenteral administration and the high cost of the
liposomal formulation prevents this treatment from reaching the
majority of patients in developing nations [3]. A stable, efficacious
oral treatment for VL that is able to withstand the rigors of tropical
climates would overcome many of the current barriers to
treatment that exist in countries with large VL-infected patient
populations. An oral lipid-based formulation of AmB (iCo-009)
was recently developed and evaluated in animal models of
systemic fungal infections and VL [4,5,6]. iCo-009 demonstrated
significant antifungal and antiparasitic activity as well as an
excellent drug stability profile at 4uC [4,5,6].
The goal of the current study was to develop potential oral
formulations of AmB that are a) stable at the temperatures of
WHO Climatic Zones 3 and 4 (30–43uC); b) retain AmB stability
in simulated gastric and intestinal fluids and c) exhibit significant
antileishmanial activity in a VL-infected murine model. We have
now developed a number of lipid-based self-emulsifying formula-
tions which exhibit AmB chemical stability in FaSSIF and
temperature stability at 43uC. The temperature stability of AmB
at 30 and 43uC in a series of lipid formulations (iCo-010-013) are
www.plosntds.org 1 December 2010 | Volume 4 | Issue 12 | e913described, which indicate that formulations based on mono- and
di-glycerides and Vitamin E-TPGS provide excellent temperature
stability for AmB. Furthermore, these formulations show good
stability in simulated intestinal fluids, which mimic the degradative
stress of oral administration. A nanoemulsion (with droplet
diameters ,1 mm) forms in these fluids upon mixing at 37uC,
facilitating absorption of these AmB-lipid compositions. In
addition, we provide data that demonstrate the significant
antileishmanial activity of one of these tropically stable, novel
lipid-based oral AmB formulations (iCo-010).
Materials and Methods
Ethics Statement
Studies in Leishmania donovani-infected BALB/c mice were
carried out according to a protocol approved by The Ohio State
University Institutional Animal Care and Use Committee
(National Institutes of Health Office of Laboratory Animal
Welfare Assurance Number A3261-01). The study was conducted
adhering to the Ohio State University’s guidelines for animal
husbandry and appropriate steps were taken to avoid or minimize
pain and suffering.
Materials
Amphotericin B (AmB; 80% purity) was purchased from Sigma
Chemical Co. (St. Louis, MO) and used as received. Ethanol
(100%) was purchased from Commercial Alcohols (Vancouver,
BC). Mono- and di-glycerides were a gift from Gattefosse ´ Canada
(Toronto, ON, Canada). D-alpha-tocopheryl polyethylene glycol
succinate (Vitamin E-TPGS; NF grade) was bought from Eastman
Chemical Co. (Kingsport, TN). Methanol, HPLC water, acetoni-
trile and acetic acid were purchased from Fisher Scientific
(Ottawa, ON Canada) and were of HPLC grade. Sodium
chloride, hydrochloric acid, sodium hydroxide, dibasic potassium
phosphate, sodium taurocholate and porcine pancreatin were
bought from Sigma Chemical Co. Egg phosphatidylcholine
(lecithin) was purchased from Avanti Polar Lipids (Alabaster, AL).
Analysis of AmB Concentration by HPLC
Chromatography conditions: The HPLC column was a BDS
Hypersil C18, 5 mm, 25064.6 mm (Thermo Scientific, Waltham,
MA), with a C18 guard column from Phenomenex (Torrance,
CA). During sample runs, the column incubator was set to 40uC.
The mobile phase consisted of acetonitrile: acetic acid: water in a
ratio of 57:4.3:38.7 (v/v/v). The injection volume was 90 mL and
the flow rate was 0.8 mL/min with a run time of 20 min. The
retention time of AmB under these conditions was 15 min. Six
triplicate standards of AmB in methanol: water (50:50 v/v) were
used for external calibration, with a linear range of 31.25–1000
ng/mL by linear regression analysis (r
2.0.999). For analysis of
AmB in lipid formulations, the samples were warmed in a 48uC
waterbath to melt the lipids, followed by vigorous vortexing for 2
min. A double dilution was then used. With a micropipettor,
100 mL were transferred to a glass vial followed by the addition of
9.9 mL methanol and vortexing for 1 min. From this dilution,
100 mL was aliquoted to another glass vial, followed by addition of
9.9 mL of methanol:water (50:50 v/v) and vortexed for 1 min,
thereby making 1:10,000 dilutions of the original samples. These
final dilutions were analyzed by HPLC as described above and
compared to the standard curve for quantification of AmB
concentration.
Formulation Stability at 30uC and 43uC
The stability testing of AmB in each of the four oral lipid
formulations (AmB in mono- and di-glycerides with or without
Vitamin E-TPGS; iCo 010-013) was performed at 30uC and 43uC
at ambient humidity (.85%). The base compositions of the
formulations are composed of mono- and diglycerides with a
mixture of glycerol and PEG1500 esters of long fatty acids with or
without Vitamin E-TPGS. iCo 010 contains 60/40 (v/v) mono-
and diglycerides with Vitamin E-TPGS; iCo 011 contains 50/50
(v/v) mono- and diglycerides with Vitamin E-TPGS; iCo 012
contains 50/50 (v/v) mono- and diglycerides without Vitamin E-
TPGS; and iCo 013 contains 60/40 (v/v) mono- and diglycerides
without Vitamin E-TPGS. For stability analysis at 30uC and 43uC,
multiple time points covering a 60 day period were chosen as part
of the accelerated temperature studies set out by the WHO to
mimic tropical climate Zone 3 and 4 conditions. Four independent
replicate samples were prepared for each time point by melting the
batch of AmB in lipids at 48uC and stirring to homogeneity,
followed by quickly aliquoting 0.5 mL of the AmpB/lipid mixture
into individual polypropylene microcentrifuge tubes. The tubes
were then sealed with parafilm. Samples were protected from light
with foil and stored in incubators at 30u or 48uC. The starting
concentration of AmB in the lipids was measured by HPLC (3–4
mg/mL depending on batch concentration). All subsequent
measurements of AmB during the course of the stability study
were performed by HPLC as described above and are reported as
‘‘% of original concentration’’ as measured on the day the sample
was aliquoted (day 0). The rate of loss of AmB per day was
calculated as: ([AmB]day 02[AmB]day 60)/60 days. =mg/mL?day
loss. These data are reported as mean 6SD for 4 independent
replicates. Statistical differences were assessed pair-wise by
Student’s t test (paired, 2-tailed) (SigmaStat v.3.5) with significance
set at p,0.05.
Stability in Simulated Fasted-State Intestinal Fluid
(FaSSIF)
Preparation of Fasted-State Simulated Intestinal Fluid without
enzymes was also prepared according to the USP V.28 and was
composed of 3.9 g/L dibasic potassium phosphate, 1.613 g/L
sodium taurocholate (=3 mM), lecithin (egg phosphatidylcholine)
0.57 g/L (=0.75 mM), potassium chloride 7.7 g/L dissolved in
water and with sufficient hydrochloric acid to adjust the pH to 6.5.
AmB formulations in mono- and di-glycerides with or without
Vitamin E-TPGS and the corresponding drug-free vehicle controls
were melted at 48uC in a water bath followed by vigorous
Author Summary
Visceral leishmaniasis (VL) is a systemic form of a vector-
borne parasitic disease caused by obligate intra-macro-
phage protozoa of the genus Leishmania. VL is always fatal
in humans if left untreated and treatment options are
limited. Amphotericin B (AmB), a polyene antibiotic, is the
most active antileishmanial agent that currently exists.
Liposomal AmB (AmBisome) is used as first-line treatment
in developed countries [1,7,8,9,10]; however, the requisite
parenteral administration and the high cost of the
liposomal formulation prevents this treatment from
reaching the majority of patients in developing nations
[3]. A stable, efficacious oral treatment for VL that is able to
withstand the rigors of tropical climates would overcome
many of the current barriers to treatment that exist in
countries with large VL-infected patient populations. In
this study we have developed an oral formulation of AmB
that is stable in tropical conditions and exhibits significant
antileshimanial activity in mice.
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wrapped 500 mL beakers on stirring hotplates. For incubation in
FaSSIF, samples (0.5 mL) were added to 249.5 mL FaSSIF to
achieve a dilution of 1:500 v/v. The samples were mixed
vigorously at 37uC over over 4 h for FaSSIF incubation, producing
an emulsified mixture. At 0, 10, 30, 45, 60, 90, 120 and 240 min in
FaSSIF, triplicate 1 mL samples were withdrawn from the beakers
while the mixing continued. The 1 mL samples were diluted with 9
mL methanol and vortexed to clarity. Quantification of AmB
concentration was performed by ultraviolet spectroscopy (l=407)
on a Carey Bio-300 UV-visible spectrophotometer (Varian
Canada, Mississauga, Ontario) by comparison to an external
standard curve consisting of UV measurements of AmB in
methanol containing the same dilution of the corresponding
vehicle control for each formulation type. The linear range by
regression analysis was 0.5–1.75 mg/mL (r
2.0.999).
Emulsion Droplet Sizing in Simulated Fasted-State
Intestinal Fluid
The translucent emulsion formed during incubation of AmB in
oral lipids in simulated gastric or intestinal fluid tends to cream (oil
to the top of the aqueous phase) if not continuously mixed.
Therefore, 1 mL samples were obtained mid-beaker depth at 2 h
and 4 h for FaSSIF incubations during vigorous mixing and
transferred to a plastic cuvette. Samples were mixed again by
vortexing prior to placement in the sizing instrument. The
emulsion droplet size was measured by dynamic light scattering
(Malvern Zetasizer, Malvern Instruments, Worchestershire, UK)
operating with an argon laser (l=633 nm) and with the sample
holder kept at 37uC for 3 runs of 1 minute each, during which time
the measurements were stable. Intensity weighting was used. Data
are reported as the mean droplet diameter 6 standard deviation
(SD) from mean of 3 separate samples, where three runs were
averaged for each sample.
In vivo evaluation of iCo-010 in a VL-infected Murine
Model
To determine the antileishmanial activity of our oral AmB
formulation, the following studies were completed. BALB/c mice
were intravenously infected with 5610
7 Leishmania donovani LV82
promastigotes (obtained by culturing amastigotes taken directly
from the spleen of an infected hamster) seven days prior to
treatment. Following the seven days, mice were either adminis-
tered five daily doses of miltefosine at 3 mg/kg po, or iCo-010 at
2.5, 5, and 10 mg/kg po bid for five consecutive days or 20 mg/kg
po qd for five consecutive days. Appropriate vehicle controls were
also assessed. Animals were sacrificed 14 days post infection and
Leishman-Donovan units (LDU) were assessed in livers of mice
post mortem via microscopic enumeration of Giemsa-stained liver
smears.
Results
Formulation Stability
The results in Fig. 1 show that the stability of AmB in the lipid
formulations is .75% for all formulations over 60 days at 30uC
and Fig. 2 shows a similar pattern at 43uC with a slightly lower
concentration in all formulations by 60 days. After 60 days at
30uC, AmB concentrations were comparable with and without
Vitamin E-TPGS (,85% of the original concentration), but when
different proportions of mono- and di-glycerides were employed,
samples without Vitamin E-TPGS (iCo-013) contained only 75%
of the original AmB concentration compared to 91% when
Vitamin E-TPGS was included (iCo-011). The addition of
Vitamin E-TPGS did not significantly change the decomposition
rate for AmB in iCo-010 at 43uC, although there was a trend to
greater retention of AmB when Vitamin E-TPGS was included.
The rate of decomposition (mg/mL. day) of AmB in all the lipid
formulations at both temperatures is slow, as indicated in Table 1.
There was a significant decrease (p,0.01) in the rate at which the
AmB was lost in iCo-011 compared to iCo-013. This resulted in
AmB concentrations after 60 days at 43uC that were 83.4% of the
original concentration when Vitamin E-TPGS was included but
only 69.7% when it was not present. It should be noted that no
phase separation of the lipids or changes in particle size were
observed after 60 days of incubation at 43uC for iCo 010.
Stability in Simulated Fasted-State Intestinal Fluid
In simulated fasted-state intestinal fluid (FaSSIF), after 4 h of
mixing at 37uC, iCo-010 retains .95% of its original drug
Figure 1. Stability of AmB in lipid suspensions at 30uC over 60 days. Symbols: solid diamonds: iCo-010; solid squares: iCo-011; crosses: iCo-
012; open circles: iCo-013. Data represent mean 6 SD (n=4).
doi:10.1371/journal.pntd.0000913.g001
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011, iCo-012 and iCo-013 in FaSSIF shows very similar stability of
formulations containing VitE-TPGS to those without it.
Emulsion Droplet Sizing in Simulated Fasted-State
Intestinal Fluid
Assessment of emulsification in FaSSIF of AmB formulations
composed of Peceol/Gelucire 44/14 shows that the presence of
VitE-TPGS in the Peceol/Gelucire 44/14 mixture, such as in iCo-
010 and iCo-011, reduces the mean diameter and creates a more
monodisperse nanoemulsion. Emulsion droplet sizing of AmB in
iCo-013 (no VitE-TPGS) following 2 and 4 h mixing in FaSSIF at
37uC revealed the largest droplet size of approximately 700–850
nm, whereas AmpB in iCo-010 (with VitE-TPGS) had a relatively
smaller mean diameter closer to 200 nm. (Fig 4).
Considering the similar stability data for the four formulations
tested (both at elevated temperature and in simulated gastrointes-
tinal fluids) and more desirable self-emulsification properties of
iCo-010, this formulation was chosen for in vivo studies of AmpB
efficacy in an animal model of VL, as described below.
Effectiveness in VL-infected Murine Model
When given in five daily doses at 3 mg/kg po, miltefosine
resulted in 47.567.0% inhibition of liver parasites, consistent with
literature reports [6]. LDU values were not significantly different
between groups of animals receiving oral doses of a lipid-based
vehicle control bid for five days versus those receiving a single IV
saline injection. (Fig. 5). Dose response data from treatment of L.
donovani- infected BALB/c mice with 2.5, 5 and 10 mg/kg iCo-010
bid for five days is reported in Fig. 5. iCo-010 demonstrated
significant efficacy when orally administered to VL-infected mice
bid for five days (inhibition of 99%, 98%, and 83% at 10, 5 and
2.5 mg/kg compared to the vehicle control). In addition, the qd
dose of 20 mg/kg provided 96% inhibition compared to the
vehicle control. Based on data from our antifungal studies
indicating no renal toxicity (data not shown) and the level of
antileishmanial activity (Fig. 5), we are now confident that a self-
administered tropically stable oral formulation of AmB is
attainable.
Discussion
The lipid formulations of AmB based on mono- and
diglycerides 6 Vitamin E-TPGS were developed as an alternative
to the less temperature-stable monoglyceride formulation. Lipids
with a melting point above ambient temperature and with good
suspending properties, surfactant and self-emulsifying properties
were chosen as alternatives. The ratio of mono- and di-glycerides
and pegylated esters was selected based on preliminary studies of
AmB temperature stability, component miscibility and mainte-
nance of a stable suspension without phase separation. Further-
more, preliminary studies indicated that Vitamin E-TPGS in
combination with mono- and di-glycerides and pegylated esters
was tolerable in terms of maintaining a physically stable
suspension of AmB at 5 mg/mL.
The temperature stability of AmB in all the lipid formulations
was excellent, exceeding approximately 80% after 60 days at 30uC
(Fig. 1) and 75% at 43uC( Fig. 2), and exhibiting no clear
differences in the pattern of concentration loss vs. time amongst the
four preparations. Upon examining the rate of drug loss as a
function of excipient composition (Table 1), iCo-011 was slightly
more stable than iCo-10 or iCo-013 at 30uC. As expected,
addition of Vitamin E-TPGS significantly decreased the rate of
drug loss at 43uC. At 43uC, the ratio of mono- and di-glycerides
Figure 2. Stability of AmB in lipid suspensions at 43uC over 60 days. Symbols: solid diamonds: iCo-010; solid squares: iCo-011; crosses: iCo-
012; open circles: iCo-013. Data represent mean 6 SD (n=4).
doi:10.1371/journal.pntd.0000913.g002
Table 1. Decomposition rate of AmpB in lipid formulations.
Lipid formulation 30uC4 3 uC
mg/mL per day lost mg/mL per day lost
iCo-010 13.7864.49 16.3267.25
iCo-011 7.5565.75 13.6662.07
iCo-012 12.1169.76 21.3965.08
iCo-013 18.6365.73 25.8562.34
Data indicate mean rate of loss of AmB 6 SD (n=4). Results derived from the
data in Fig. 1 and 2.
doi:10.1371/journal.pntd.0000913.t001
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www.plosntds.org 4 December 2010 | Volume 4 | Issue 12 | e913and pegylated esters appears less important than the presence of
Vitamin E-TPGS, as formulations containing it showing a slower
rate of AmB loss. However, the complex and likely temperature-
dependent mechanism of interaction between AmB and the
various lipids at the molecular level has not yet been explored.
Nevertheless, these are very small differences and the biological
properties of these formulations (bioavailability, tissue drug
distribution and efficacy) would clearly be more important
parameters to govern selection of a lead candidate from this set
of formulations.
Regarding the properties of these lipid formulations in
conditions mimicking those of the gastrointestinal tract, studies
of the stability of the lipid formulations in FaSSIF demonstrate
that AmB concentration is well-maintained when incorporated
into all of the formulations, as shown in Fig. 3.
The self-emulsifying properties of these lipid formulations are
deemed important because the formation of a nanoemulsion in the
gastrointestinal tract may facilitate intestinal absorption, particu-
larly through the lymphatic transport pathway. Furthermore, a
major precipitation of the drug in gastrointestinal fluids would be
undesirable and lead to unpredictable absorption patterns. The
emulsification of the drug-lipid mixture also promotes interaction
with bile salts, which can further enhance solubilization and
absorption of the drug in the intestine. iCo-010 in FaSSIF, which
contains sodium taurocholate as the bile salt, produced a slightly
larger nanoemulsion of greater polydispersity. The emulsification
Figure 3. Stability of AmB in lipid formulations in fasted-state simulated intestinal fluid (FaSSIF) at 37uC. Symbols: solid diamonds: iCo-
010; solid squares: iCo-011; crosses: iCo-012; open circles: iCo-013.Data represent mean 6 SD (n=3).
doi:10.1371/journal.pntd.0000913.g003
Figure 4. Emulsion droplets sizing in fasted-state simulated intestinal fluid. Symbols are white bars: iCo-010; black bars: iCo-011; dotted
bars: iCo-012; hatched bars: iCo-013. Data represent mean 6 SD (n=3).
doi:10.1371/journal.pntd.0000913.g004
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TPGS in FaSSIF are an ongoing study which should allow for the
further discernment of the role of Vitamin E-TPGS in the physical
properties of these suspensions.
Considering the similar stability data for the 4 formulations
tested (both at elevated temperature and in simulated gastrointes-
tinal fluids) and more desirable self-emulsification properties of
iCo-010, this formulation was chosen for in vivo studies of AmpB
efficacy in an animal model of VL. The demonstrated efficacy of
this formulation is likely due to a combination of increased
solubility, improved gastrointestinal stability and enhanced
membrane permeability. In addition, oral administration of a
lipid-based formulation favors lymphatic transport. As VL
parasites disseminate through the lymphatic and vascular system,
infecting macrophages and infiltrating the bone marrow, liver and
spleen, the lipid carrier may assist in delivering the drug to the site
of greatest infection. Taking into consideration the short treatment
course in this study, it is conceivable that longer treatment would
completely eradicate VL in all treated animals. To the best of our
knowledge, these data represent the first tropically stable oral AmB
formulations to exhibit significant efficacy against Leishmania
donovani (the parasite responsible for VL) in an infected mouse
model.
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